Previous close | 93.26 |
Open | 92.07 |
Bid | 71.95 |
Ask | 74.65 |
Strike | 840.00 |
Expiry date | 2024-07-19 |
Day's range | 92.07 - 93.26 |
Contract range | N/A |
Volume | |
Open interest | 1 |
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Tuesday, the FDA said it would convene an in-person meeting of the Peripheral and Central Nervous System Drugs Advisory Committee on Monday, June 10, 2024, to discuss Eli Lilly and Co’s (NYSE:LLY) donanemab for early symptomatic Alzheimer’s disease. The open public hearing portion of the meeting will be conducted virtually. The Phase 3 study submitted as part of this application, TRAILBLAZER-ALZ 2, is a double-blind, placebo-controlled study to evaluate the safety and efficacy of donanemab in pa
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.